You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Populating MPS database with data from multi-organ, human-on-a-chip microphysiological systems

    SBC: HESPEROS, INC            Topic: 100

    Project Summary/Abstract: As stated in the Notice of Special Interest announcement, there is a need to populate the recently established MPS database with existing data generated by organ-on-a-chip systems. Having a centralized, public database with data from all available MPS systems will accelerate development and acceptance of the technology ultimately bringing better therapies to patients fast ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. An Innovative Platform for Objective Monitoring of Instrumental Activities of Daily Living

    SBC: BIOSENSICS LLC            Topic: NIA

    With a Phase I/II STTR grant award from NIA, BioSensics in collaboration with Baylor College of Medicine (BCM) successfully developed and commercialized an advanced physical activity monitoring system (PAMSys™) for older adults. PAMSys enables continuous remote monitoring of physical activity, fall risk, and fall incidents. The fall detection technology of PAMSys has become the gold standard in ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. A Phase 2b Clinical Trial to Study the Efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) to Treat Aging Frailty

    SBC: Longeveron LLC            Topic: NIA

    Aging Frailty is a biologically driven geriatric syndrome of multisystem physiological decline that is distinct from normal aging and disproportionately increases vulnerability to adverse clinical outcomes. Frailty has an overall prevalence of 10% of those 65 years and older, and there is growing awareness in the geriatric community to diagnose and treat this condition, as it is not an inevitable ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. CFI Pathogen Inactivation of Human Plasma Units

    SBC: APHIOS CORPORATION            Topic: NHLBI

    PROJECT SUMMARY The rapid spread of the Zika virus, which can have a significant impact on neurological disorders in unborn fetuses and potentially adults, the recent outbreak of the extremely virulent Ebola virus, periodic emergence of SARS, recurrent outbreaks of potentially pandemic strains of influenza such as H5N1, the continuing epidemic of MERS and the worldwide AIDS epidemic have highlight ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Increasing size of Phase 2b clinical trial to 60 patients

    SBC: PAIN THERAPEUTICS, INC.            Topic: NIA

    Project Summary/Abstract PTI-125 is a novel small molecule Alzheimer’s disease (AD) therapeutic candidate with a novel target and mechanism of action. PTI-125 binds and reverses an altered conformation of the scaffolding protein filamin A (FLNA) to prevent Aβ42’s tight binding to and toxic signaling via the α7-nicotinic acetylcholine receptor (α7nAChR) as well as Aβ42’s aberrant activati ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Completion of IND-package for a novel, non-narcotic painkiller

    SBC: BLUE THERAPEUTICS, INC.            Topic: NIDA

    Project Summary Opioids like morphine and hydrocodone are generally the most effective therapeutics for treatment of moderate to severe pain. However, their use is limited by serious side effects - tolerance, constipation, respiratory depression, physical dependence and high addictive potential. The frequency of clinical pain, coupled with a lack of alternative therapeutic options has led to a nat ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Functional integrated human-on-a-chip systems for Alzheimer's research

    SBC: HESPEROS, INC            Topic: NIA

    Project SummaryThe goal of this proposal, at the end of the Phase II effort, is to have a service available to academia and industry to screen drugs for Alzheimer’s to predict patient outcomes and determine how potential therapeutics are delivered to the CNS. There are currently few companies able to offer multi-organ evaluation with a recirculating medium utilizing functional readouts, and none ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. A Rapid Breath Test for Invasive Aspergillosis

    SBC: VOLATYLIX INC            Topic: NIAID

    Invasive aspergillosis (IA) is a leading cause of morbidity and death in immunocompromised patients, with over 30 million individuals at risk for IA and at least 200,000 IA cases developing worldwide each year. Despite the development of potent triazole antifungal drugs for the treatment of IA, IA-associated mortality is still 22-40%. Timely and accurate diagnosis of IA, in conjunction with prompt ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. An automated platform for direct-from-specimen identification of pathogens common in endocarditis

    SBC: HELIXBIND, INC.            Topic: NIAID

    PROJECT SUMMARY Infective Endocarditis (IE) is a life-threatening disease that affects roughly 45,000 Americans annually. IE is characterized by microbial vegetations on the endocardial surface which induce serious heart damage and persistent bloodstream infections (BSIs) leading to sepsis. Left untreated IE is fatal. Among the criteria to establish IE and treat patients most effectively, blood cu ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Novel Spectinamide Antibiotics for the Treatment of MDR/XDR Tuberculosis

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    Summary/AbstractThe overall objective of this project is to develop a novel chemical class of tuberculosis (TB) therapeutic agents, the spectinamide series, for use against MDR and XDR strains of Mycobacterium tuberculosis (Mtb) and identify, through a series of in vivo efficacy assays and preclinical pharmacokinetics, toxicology and safety pharmacology studies, a clinical candidate. TB is a letha ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government